Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study

Pau Montesinos, Gail J. Roboz, Claude Eric Bulabois, Marion Subklewe, Uwe Platzbecker, Yishai Ofran, Cristina Papayannidis, Agnieszka Wierzbowska, Ho Jin Shin, Vadim Doronin, Stefan Deneberg, Su Peng Yeh, Mehmet Ali Ozcan, Steven Knapper, Jorge Cortes, Daniel A. Pollyea, Gert Ossenkoppele, Sergio Giralt, Hartmut Döhner, Michael HeuserLiang Xiu, Indrajeet Singh, Fei Huang, Julie S. Larsen, Andrew H. Wei

Research output: Contribution to journalArticle

2 Scopus citations

Fingerprint Dive into the research topics of 'Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study'. Together they form a unique fingerprint.

Medicine & Life Sciences